{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T08:39:53Z","timestamp":1778402393345,"version":"3.51.4"},"reference-count":60,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS091238"],"award-info":[{"award-number":["R01NS091238"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The search for efficacious treatment of neurodegenerative and progressive neuroinflammatory diseases continues, as current therapies are unable to halt or reverse disease progression. PACAP represents one potential therapeutic that provides neuroprotection effects on neurons, and also modulates inflammatory responses and circulation within the brain. However, PACAP is a relatively long peptide hormone that is not trivial to synthesize. Based on previous observations that the shortened isoform PACAP1\u201323 is capable of inducing neuroprotection in vitro, we were inspired to synthesize shortened glycopeptide analogues of PACAP1\u201323. Herein, we report the synthesis and in vitro characterization of glycosylated PACAP1\u201323 analogues that interact strongly with the PAC1 and VPAC1 receptors, while showing reduced activity at the VPAC2 receptor.<\/jats:p>","DOI":"10.3390\/molecules26164932","type":"journal-article","created":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T22:51:27Z","timestamp":1629067887000},"page":"4932","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Synthesis and In Vitro Characterization of Glycopeptide Drug Candidates Related to PACAP1\u201323"],"prefix":"10.3390","volume":"26","author":[{"given":"Christopher R.","family":"Apostol","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, BIO5, The University of Arizona, 1306 E. University Blvd, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2566-9312","authenticated-orcid":false,"given":"Parthasaradhireddy","family":"Tanguturi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Medicine, The University of Arizona, 1501 N. Campbell Ave, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos Z.","family":"Szab\u00f2","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, BIO5, The University of Arizona, 1306 E. University Blvd, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Varela","sequence":"additional","affiliation":[{"name":"Facultat de Qu\u00ecmica Tarragona, Universitat Rovera I Virgili, 43007 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago","family":"Gilmartin","sequence":"additional","affiliation":[{"name":"Facultat de Qu\u00ecmica Tarragona, Universitat Rovera I Virgili, 43007 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Streicher","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Medicine, The University of Arizona, 1501 N. Campbell Ave, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Polt","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, BIO5, The University of Arizona, 1306 E. University Blvd, Tucson, AZ 85721, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Prevalence of Parkinson\u2019s disease across North America","volume":"4","author":"Marras","year":"2018","journal-title":"npj Park. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"(2017). Alzheimer\u2019s Association; 2017 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement., 13, 325\u2013373.","DOI":"10.1016\/j.jalz.2017.02.001"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3171\/2017.10.JNS17352","article-title":"Estimating the global incidence of traumatic brain injury","volume":"130","author":"Dewan","year":"2019","journal-title":"J. Neurosurg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/CIRCRESAHA.116.308413","article-title":"Global Burden of Stroke","volume":"120","author":"Feigin","year":"2017","journal-title":"Circ. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/npp.2011.212","article-title":"Parkinson\u2019s Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa","volume":"37","author":"Smith","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bjoms.2011.03.004","article-title":"Traumatic brain injury: Review of current management strategies","volume":"50","author":"Tsang","year":"2012","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-1-14","article-title":"Microglia and neuroinflammation: A pathological perspective","volume":"1","author":"Streit","year":"2004","journal-title":"J. Neuroinflammation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: A target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nri.2016.123","article-title":"Cytokine networks in neuroinflammation","volume":"17","author":"Becher","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.aag2590","article-title":"How neuroinflammation contributes to neurodegeneration","volume":"353","author":"Ransohoff","year":"2016","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.expneurol.2017.08.013","article-title":"AMPK activation: Role in the signaling pathways of neuroinflammation and neurodegeneration","volume":"298","author":"Peixoto","year":"2017","journal-title":"Exp. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2014.38","article-title":"Microglial priming in neurodegenerative disease","volume":"10","author":"Perry","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrn2038","article-title":"Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms","volume":"8","author":"Block","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1073\/pnas.082112699","article-title":"Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death","volume":"99","author":"Vaudry","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12640-010-9186-y","article-title":"Neuroprotective Effects of PACAP Against Ethanol-Induced Toxicity in the Developing Rat Cerebellum","volume":"19","author":"Botia","year":"2010","journal-title":"Neurotox. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.regpep.2004.05.014","article-title":"Effects of pituitary adenylate cyclase activating polypeptide in a rat model of traumatic brain injury","volume":"123","author":"Farkas","year":"2004","journal-title":"Regul. Pept."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.regpep.2004.05.016","article-title":"Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats","volume":"123","author":"Reglodi","year":"2004","journal-title":"Regul. Pept."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.peptides.2011.04.003","article-title":"PACAP and a novel stable analog protect rat brain from ischemia: Insight into the mechanisms of action","volume":"32","author":"Dejda","year":"2011","journal-title":"Peptides"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.regpep.2006.06.016","article-title":"Neuroprotection by endogenous and exogenous PACAP following stroke","volume":"137","author":"Chen","year":"2006","journal-title":"Regul. Pept."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1096\/fj.05-4812fje","article-title":"The neuropeptide PACAP promotes ?-secretase pathway for processing Alzheimer amyloid precursor protein","volume":"20","author":"Kojro","year":"2006","journal-title":"FASEB J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2174\/1568026619666190709092647","article-title":"Targeting the PAC1 Receptor for Neurological and Metabolic Disorders","volume":"19","author":"Liao","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_22","first-page":"307","article-title":"Neuroprotective potential of three neuropeptides PACAP, VIP and PHI","volume":"57","author":"Dejda","year":"2005","journal-title":"Pharmacol. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1124\/pr.109.001370","article-title":"Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery","volume":"61","author":"Vaudry","year":"2009","journal-title":"Pharmacol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/aps.2011.170","article-title":"Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors","volume":"33","author":"Pal","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tips.2013.11.001","article-title":"Insights into the structure of class B GPCRs","volume":"35","author":"Hollenstein","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.peptides.2015.01.009","article-title":"A structure\u2013function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists","volume":"66","author":"Mantey","year":"2015","journal-title":"Peptides"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bcp.2010.11.015","article-title":"Design and in vitro characterization of PAC1\/VPAC1-selective agonists with potent neuroprotective effects","volume":"81","author":"Doan","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.2174\/138161211795589337","article-title":"Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug","volume":"17","author":"Bourgault","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1021\/jm900291j","article-title":"Molecular and Conformational Determinants of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) for Activation of the PAC1 Receptor","volume":"52","author":"Bourgault","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_30","first-page":"239","article-title":"Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist","volume":"207","author":"Robberecht","year":"1992","journal-title":"JBIC J. Biol. Inorg. Chem."},{"key":"ref_31","first-page":"347","article-title":"Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified at position 1, 2, 3, 20, or 21","volume":"42","author":"Robberecht","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0167-0115(96)00010-9","article-title":"C-Terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP2 recombinant receptors","volume":"62","author":"Gourlet","year":"1996","journal-title":"Regul. Pept."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"129410","DOI":"10.1016\/j.bbagen.2019.08.003","article-title":"The amidated PACAP1\u201323 fragment is a potent reduced-size neuroprotective agent","volume":"1863","author":"Lamine","year":"2019","journal-title":"Biochim. et Biophys. Acta (BBA)-Gen. Subj."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1113\/jphysiol.2003.053835","article-title":"Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents","volume":"554","author":"Fizanne","year":"2004","journal-title":"J. Physiol."},{"key":"ref_35","first-page":"690","article-title":"Passage of pituary adenylate cyclase activating polypeptide1-27 and pituary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier","volume":"267","author":"Banks","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.peptides.2015.03.010","article-title":"Peptides and the blood\u2013brain barrier","volume":"72","author":"Banks","year":"2015","journal-title":"Peptides"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: Historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorganic Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.drudis.2013.05.011","article-title":"Future directions for peptide therapeutics development","volume":"18","author":"Kaspar","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"170369","DOI":"10.1016\/j.peptides.2020.170369","article-title":"Glycopeptide drugs: A pharmacological dimension between \u201cSmall Molecules\u201d and \u201cBio-logics\u201d","volume":"131","author":"Apostol","year":"2020","journal-title":"Peptides"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fphar.2013.00155","article-title":"Lipid- and sugar-modified endomorphins: Novel targets for the treatment of neuropathic pain","volume":"4","author":"Varamini","year":"2013","journal-title":"Front. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1039\/C5SC04392A","article-title":"Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides","volume":"7","author":"Moradi","year":"2016","journal-title":"Chem. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fchem.2015.00040","article-title":"CNS active O-linked glycopeptides","volume":"3","author":"Jones","year":"2015","journal-title":"Front. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neulet.2012.10.029","article-title":"CNS penetration of the opioid glycopeptide MMP-2200: A microdialysis study","volume":"531","author":"Mabrouk","year":"2012","journal-title":"Neurosci. Lett."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Bartlett, M.J., Mabrouk, O.S., Szab\u00f2, L., Flores, A.J., Parent, K.L., Bidlack, J.M., Heien, M.L., Kennedy, R.T., Polt, R., and Sherman, S.J. (2020). The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010020"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1124\/jpet.108.138180","article-title":"Behavioral Pharmacology of the \u03bc\/\u03b4 Opioid Glycopeptide MMP2200 in Rhesus Monkeys","volume":"326","author":"Carmo","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1021\/jm400879w","article-title":"Can Amphipathic Helices Influence the CNS Antinociceptive Activity of Glycopeptides Related to \u03b2-Endorphin?","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.118.254854","article-title":"A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction","volume":"369","author":"Hay","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1747-0285.2007.00462.x","article-title":"Glycosylation Improves the Central Effects of DAMGO","volume":"69","author":"Lowery","year":"2007","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4155\/fmc.11.195","article-title":"Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins","volume":"4","author":"Li","year":"2012","journal-title":"Futur. Med. Chem."},{"key":"ref_51","unstructured":"Bernard, K., Bartlett, M.J., Liu, C., Molnar, G., Apostol, C.R., Szab\u00f2, L.Z., Sherman, S.J., Madhavan, L., Streicher, J.M., and Polt, R. (2021, January 11\u201313). Evaluation of a neuroprotective PACAP glycopeptide as systemically delivered CNS active drug to treat Parkinson\u2019s disease. Proceedings of the Society for Neuroscience, Chicago, IL, USA. Available online: https:\/\/www.sfn.org\/meetings\/virtual-events\/sfn-global-connectome-a-virtual-event\/abstracts."},{"key":"ref_52","unstructured":"Apostol, C.R., Bernard, K., Molnar, G., Bartlett, M.J., Szab\u00f2, L., Liu, C., Ortiz, J.B., Saber, M., Giordano, K.R., and Green, T.F.R. Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP with Neuroprotective Potential for Stroke, Traumatic Brain Injury, and Parkinsonism, Unpublished work."},{"key":"ref_53","unstructured":"Kesharwani, P., and Gupta, U. (2018). Physiology of the Blood\u2013Brain Barrier and Mechanisms of Transport Across the BBB. Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors, Elsevier Academic Press."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.carres.2012.01.008","article-title":"Glycosylation of \u03b1-amino acids by sugar acetate donors with InBr3. Minimally competent Lewis acids","volume":"351","author":"Lefever","year":"2012","journal-title":"Carbohydr. Res."},{"key":"ref_55","first-page":"631","article-title":"The road to the synthesis of \u201cdifficult peptides\u201d","volume":"45","author":"Puche","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"ref_56","first-page":"853","article-title":"Piperidine\u2013mediated Side Product Formation for Asp(OBut)\u2013containing Peptides","volume":"7","author":"Beyermann","year":"1994","journal-title":"J. Chem. Soc. Chem. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8595","DOI":"10.1016\/j.tet.2011.08.046","article-title":"Aspartimide formation in peptide chemistry: Occurrence, prevention strategies and the role of N-hydroxylamines","volume":"67","author":"Albericio","year":"2011","journal-title":"Tetrahedron"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"9689","DOI":"10.1016\/0040-4039(94)88360-2","article-title":"Aspartimide formation in base-driven 9-fluorenylmethoxycarbonyl chemistry","volume":"35","author":"Yang","year":"1994","journal-title":"Tetrahedron Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10989-008-9154-z","article-title":"Application of Dmb-Dipeptides in the Fmoc SPPS of Difficult and Aspartimide-Prone Sequences","volume":"14","author":"Cardona","year":"2008","journal-title":"Int. J. Pept. Res. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/(SICI)1099-1387(199909)5:9<403::AID-PSC213>3.0.CO;2-S","article-title":"The synthesis of \u201cdifficult\u201d peptides using 2-hydroxy-4- methoxybenzyl or pseu-doproline amino acid building blocks: A comparative study","volume":"5","author":"Sampson","year":"1999","journal-title":"J. Pept. Sci."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/16\/4932\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:46:09Z","timestamp":1760165169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/16\/4932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":60,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["molecules26164932"],"URL":"https:\/\/doi.org\/10.3390\/molecules26164932","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,14]]}}}